News Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-16 am EDT			5-day change	1st Jan Change
387 ^JPY	-1.28%		-4.91%	-16.95%

Apr. 02	Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	MT
Apr. 02	Roivant's anti-inflammatory drug succeeds in mid-stage study	RE

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	Apr. 02	MT
Roivant's anti-inflammatory drug succeeds in mid-stage study	Apr. 02	RE
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	Mar. 17	MT
Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from S&P Japan 500	Mar. 17	CI
Sumitomo Pharma : Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka	Mar. 15	PU
Sumitomo Pharma Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka	Mar. 15	CI
Sumitomo Pharma Announces Availability of ORGOVYX in Canada, the First and Only Oral Androgen Deprivation Therapy Treatment for Men with Advanced Prostate Cancer	Mar. 13	AQ
US Inflation Report Lifts Asian Stock Markets	Mar. 01	MT
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	Feb. 16	MT
Japan's Nikkei slips after Fed chair signals delay in rate cut	Jan. 31	RE
Transcript : Sumitomo Pharma Co., Ltd., Q3 2024 Earnings Call, Jan 31, 2024	Jan. 31
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	Jan. 31	CI
Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	Jan. 31	CI
Fed, China Property Outlooks Roil Asian Stock Markets	Jan. 30	MT
Poxel Announces its Financial Calendar for 2024	Jan. 04	AQ
Japan's Nikkei rounds off 2023 with biggest yearly gain in a decade	Dec. 29	RE
Sumitomo Pharma : Start of Investigator-Initiated Clinical Study of iPS Cell-Derived Dopaminergic Progenitor Cells for Parkinson’s Disease in the United States	Dec. 25	PU
Poxel Provides Corporate Update	Dec. 22	AQ
Interest Rates, China Housing Measures Lift Asian Stock Markets	Dec. 15	MT
Sumitomo Pharma Presents Encouraging New Data on DSP-5336 Clinical Activity at the American Society of Hematology Annual Meeting	Dec. 12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sumitomo Pharma Co., Ltd.

Equities

4506

JP3495000006

Summary

Filters